Phosphorylated Tau (p-Tau) biomarkers represent a critical class of fluid and imaging biomarkers for diagnosing and monitoring neurodegenerative diseases, particularly Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). Tau protein is a microtubule-associated protein that, when hyperphosphorylated, forms neurofibrillary tangles (NFTs) — one of the hallmark pathological features of AD[@grundkeiqbal1986].
Phosphorylated Tau species in cerebrospinal fluid (CSF) and blood reflect neuronal injury and tau pathology burden in the brain. Different p-Tau isoforms (p-Tau181, p-Tau217, p-Tau231, p-Tau205) have distinct diagnostic performance characteristics and may represent different stages or types of tau pathology[@janelidze2020][@blennow2020].
Within the AT(N) biomarker framework, p-Tau biomarkers map to the T (Tau) component:
| AT(N) Domain |
Biomarker |
What It Measures |
| A (Amyloid) |
CSF Aβ42/40, Amyloid PET |
Amyloid plaque burden |
| T (Tau) |
CSF/Plasma p-Tau181, p-Tau217, p-Tau231 |
Tau phosphorylation and pathology |
| (N) (Neurodegeneration) |
CSF t-Tau, MRI atrophy, FDG-PET |
Neuronal injury and atrophy |
P-Tau biomarkers are the most specific fluid markers for separating AD from other neurodegenerative diseases. They show a dose-response relationship with amyloid pathology: higher amyloid burden correlates with elevated p-Tau levels[@swarup2023].
- First characterized: 2009
- Primary use: Alzheimer's disease diagnosis, differential from other dementias
- Source: CSF, plasma, serum
- Specificity: Distinguishes AD from frontotemporal dementia, Lewy body dementia, and vascular dementia with ~85% accuracy[@hansson2022]
- Regulatory status: FDA-cleared (Lumipulse G p-Tau181, Roche Elecsys p-Tau 181) for AD diagnosis[@fda2022]
- Mechanism: Phosphorylation at threonine 181 by GSK-3β and CDK5 kinases; released into CSF via exosome-mediated transport across the blood-brain barrier
- First characterized: 2020
- Primary use: Early AD detection, amyloid status determination, preclinical AD
- Source: CSF, plasma, serum
- Advantage: Highest correlation with amyloid PET positivity and earliest detectable biomarker in the AD continuum[@palmqvist2021]
- Performance: AUC 0.94 in distinguishing AD from controls, outperforming p-Tau181 and p-Tau231 in head-to-head studies[@cullen2023]
- Regulatory status: FDA-cleared (Lumipulse G p-Tau217, ALZpath Dx p-Tau217 plasma assay)
- Mechanism: Phosphorylation at threonine 217; produced by sequential phosphorylation by PKA and GSK-3β
- First characterized: 2012
- Primary use: Early preclinical detection, even before p-Tau181 elevation
- Source: CSF, plasma
- Advantage: Elevated earliest in disease progression; elevated even in cognitively normal individuals with amyloid pathology[@buchhave2010]
- Performance: Superior to p-Tau181 and p-Tau217 for discriminating AD from other neurodegenerative diseases in some studies[@janelidze2020]
- Clinical utility: Demonstrated in primary care settings for screening[@thijssen2024]
- Primary use: Research use; emerging marker with limited clinical data
- Source: CSF, plasma
- Advantage: May reflect specific NFT pathology patterns; early data suggest unique stage-dependent changes
- Status: Not yet validated for routine clinical use
- AD diagnosis: p-Tau181 and p-Tau217 have FDA-cleared assays for AD diagnosis[@fda2022]
- Differential diagnosis: Distinguishes AD from frontotemporal dementia, Lewy body dementia, vascular dementia, and primary psychiatric disorders[@rascovsky2011]
- Progression monitoring: CSF p-Tau levels correlate with cognitive decline and brain atrophy rates[@jack2018]
- Preclinical screening: p-Tau231 elevated in cognitively normal amyloid-positive individuals
- Clinical trials: Used as enrollment biomarkers and outcome measures in anti-amyloid and anti-tau therapeutic trials[@cummings2023]
- Biomarker discovery: P-Tau species serve as surrogate endpoints for drug efficacy[@koychev2020]
- Mechanistic studies: P-Tau species provide insight into tau kinase and phosphatase activity in vivo
| Biomarker |
Sensitivity |
Specificity |
AUC |
Stage Detected |
Sample Type |
| p-Tau181 |
85% |
85% |
0.90 |
Clinical AD |
CSF, Plasma |
| p-Tau217 |
90% |
88% |
0.94 |
Preclinical AD |
CSF, Plasma |
| p-Tau231 |
80% |
82% |
0.85 |
Preclinical AD |
CSF, Plasma |
| p-Tau205 |
~75% |
~78% |
~0.82 |
Research |
CSF |
Note: Performance varies by study population, assay platform, and cutoff values. Plasma p-Tau217 shows comparable performance to CSF p-Tau217 in head-to-head validation[@janelidze2022].
- p-Tau is more specific to AD pathology than t-Tau
- t-Tau is elevated in multiple neurological conditions (stroke, trauma, other dementias)
- p-Tau/t-Tau ratio improves specificity over either marker alone[@mattssoncarlgren2023]
- p-Tau captures disease-specific tau phosphorylation, while t-Tau reflects all tau release (physiological and pathological)
- p-Tau CSF/plasma reflects soluble phosphorylated tau species
- Tau PET binds to aggregated fibrillar tau in NFTs
- p-Tau and Tau PET show moderate correlation (r=0.4–0.6) but measure different tau pools[@smith2022]
- p-Tau fluid biomarkers change earlier than Tau PET in the disease course
- p-Tau is more accessible (no radiation, lower cost) but less spatially resolved
The diagnostic accuracy hierarchy from best to least among p-Tau isoforms:
- p-Tau217: Highest AUC, best amyloid PET correlation, most specific for AD
- p-Tau181: Most validated, FDA-cleared, broad clinical use
- p-Tau231: Best for earliest preclinical detection
- p-Tau205: Research use only
- p-Tau181 shows similar diagnostic performance: AUC 0.88 for AD vs. controls
- Plasma p-Tau217 validated in Japanese cohorts with comparable sensitivity[@kawasaki2025]
- Population-specific cutoff values established for Japanese populations
- Reference ranges differ slightly due to baseline tau concentration differences
- p-Tau217 performance: sensitivity 87%, specificity 89% in Korean cohorts
- p-Tau231 elevated in preclinical stages (Korean cognitively normal amyloid-positive individuals)
- Cross-validation with Japanese data confirms assay robustness across East Asian populations
¶ Chinese Cohorts (CANDI, Shanghai Cohort)
- p-Tau181 diagnostic accuracy: AUC 0.87–0.91 in Chinese AD patients
- Multi-center validation across Peking Union Medical College, Shanghai Jiaotong
- Ethnic-specific reference ranges established for CSF p-Tau biomarkers
The development of ultrasensitive immunoassays (Simoa, Lumipulse, ECiA) has enabled accurate plasma p-Tau measurement outside of CSF collection[@karikari2020].
| Test |
p-Tau Species |
Platform |
Regulatory Status |
| ALZpath Dx |
p-Tau217 |
ECiA |
FDA-cleared (2024) |
| Roche Elecsys |
p-Tau 181 |
ECiA |
FDA-cleared (2022) |
| Lumipulse G |
p-Tau181, p-Tau217 |
CLEIA |
FDA-cleared |
| Quanterix Simoa |
p-Tau181/217/231 |
Simoa |
Research Use Only |
| C2N Precivity |
p-Tau217 (plasma) |
LC-MS/MS |
CLIA-certified LDT |
Plasma p-Tau217 shows comparable performance to CSF p-Tau217 in head-to-head studies[@janelidze2022]:
- AUC difference <0.02 between plasma and CSF
- At-home blood collection now possible with finger-stick dried blood spot (DBS) kits[@ahead2024]
- Plasma p-Tau181 has slightly lower performance than CSF p-Tau181 (AUC 0.87 vs 0.90)
P-Tau biomarkers show progressive increases across the AD continuum:
- Cognitively normal, amyloid-negative: Baseline levels
- Cognitively normal, amyloid-positive: p-Tau231 elevated first, then p-Tau181
- MCI due to AD: All p-Tau isoforms elevated
- AD dementia: Peak levels, correlation with Braak stage[@swarup2023]
Annual p-Tau increases in CSF:
- p-Tau181: ~4–6 pg/mL/year increase in converters
- p-Tau217: ~2–3 pg/mL/year increase in converters
- Longitudinal trajectories predict cognitive decline rate[@berron2023]
Anti-amyloid therapies (lecanemab, donanemab) reduce p-Tau181 levels:
- Lecanemab: 22–28% reduction in plasma p-Tau181 at 18 months[@mintun2021]
- Donanemab: 20–35% reduction in p-Tau181, more pronounced in early-stage patients
- P-Tau reduction correlates with clinical benefit and amyloid plaque removal[@blennow2023]
- p-Tau217 may serve as a more sensitive treatment response marker than p-Tau181
| Factor |
Recommendation |
Impact |
| Sample collection |
LP performed in morning (optional) |
Minimize diurnal variation |
| Tube type |
Polypropylene or silicone-coated |
Prevents adsorption |
| Centrifugation |
2,000 × g, 15 min, 4°C within 1h |
Standardizes sample quality |
| Storage |
-80°C, avoid freeze-thaw cycles |
Preserves biomarker stability |
| Hemolytic samples |
Exclude if visibly red |
Hemoglobin interferes with assay |
| Sample volume |
0.5–1 mL CSF minimum |
Varies by assay platform |
P-Tau combined with other biomarkers improves diagnostic accuracy:
- p-Tau217 + Aβ42/40: AUC improves to 0.97+ for AD diagnosis
- p-Tau181 + NfL: Improves prognostic accuracy for progression from MCI to AD
- p-Tau231 + GFAP: Best combination for preclinical AD detection[@nakamura2023]
- p-Tau217 + p-Tau181 ratio: Distinguishes AD from other tauopathies
Integration with neurodegeneration markers (t-Tau, NfL) provides A+T+N profiles:
- A+T+N+: Confident AD
- A-T-N+: Non-AD neurodegeneration
- A+T-N+: Prodromal AD
- Anti-amyloid therapies reduce p-Tau181 levels, suggesting downstream effects on tau pathology[@mintun2021]
- P-Tau reduction correlates with clinical benefit in trials[@blennow2023]
- P-Tau isoforms may guide selection of tau-targeting therapies[@guo2023]
- Baseline p-Tau levels predict treatment response to anti-amyloid therapies[@therriault2023]
- P-Tau217-high patients may derive greater benefit from anti-tau therapies
- CSF p-Tau231 as primary care screening tool: Thijssen et al. demonstrated clinical utility in primary care settings[@thijssen2024]
- Plasma p-Tau217 cross-validated in 4 continents: Global assay validation confirms robustness
- Fourteen years of CSF biomarker data: Blennow et al. review maps p-Tau evolution from research to clinical practice[@blennow2024]
- Longitudinal p-Tau trajectories: Distinct patterns for typical vs. atypical AD onset
- Tau phosphorylation site mapping: Over 40 phosphorylation sites on tau identified; p-Tau199, p-Tau202, p-Tau205 emerging as research markers
¶ Cost and Accessibility
| Test Type |
Approximate Cost |
Turnaround |
Accessibility |
| CSF p-Tau181/217 |
$300–500 |
1–3 days |
Requires lumbar puncture |
| Plasma p-Tau181 |
$150–250 |
1–3 days |
Blood draw |
| Plasma p-Tau217 |
$200–400 |
3–7 days |
Limited availability |
| Tau PET |
$3,000–6,000 |
1–2 weeks |
PET center required |
| Dried blood spot (DBS) |
$50–150 |
5–10 days |
Mail-in collection |
- Cross-reactivity with non-AD tauopathies (CBD, PSP, PART)
- Pre-analytical sensitivity (sample handling critical)
- Assay variability across platforms
- Limited longitudinal data in some populations
- p-Tau217 not yet universally available in clinical labs